Heparin and Abciximab Reviparin and Abciximab

In a randomized and placebo-controlled parallel group design, Klinkhardt et al. (50) studied the pharmacodynamic effect of unfractionated heparin or a low-molecular-weight heparin, reviparin, on efficacy outcomes for abciximab or tirofiban. Abciximab is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa. The pharmacodynamic effects measured were bleeding time, fibrinogen binding at the GP IIb/IIIa receptor, expression of the platelet secretion marker CD62, and ADP (20 pM) and collagen (5 mg/mL) induced platelet aggregation. The results of the study showed that unfractionated heparin attenuated platelet aggregation and fibrinogen binding induced by abciximab or tirofiban, but reviparin did not exert any effect on their pharmacodynamic characteristics. According to the authors, the study suggests an advantage of reviparin over unfractionated heparin when given with abciximab or tirofiban.

0 0

Post a comment